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Abstract
To study desensitization and glycosylation of the type I pituitary adenylate cyclase-activating polypeptide (PACAP)
receptor (PAC1R), a hemagglutinin (HA) epitope was inserted within the N-terminal extracellular domain, allowing
immunological detection of PAC1R both in intact and permeabilized cells. PAC1R was tagged without loss of functions in
ligand binding and ligand-stimulated cAMP production. In transiently transfected COS-7 cells, PAC1R was localized both in
the plasma membrane and the cytoplasm around the nucleus. By immunoblot analysis, the immunoreactive bands with
relative molecular masses ranging from 45 to 70 kDa were detected in the membrane fractions of PAC1R-expressing COS-7
cells. Digestion of the membranes with endoglycosidase F or treatment of the cells with tunicamycin decreased the size of the
receptor to major bands of smaller size (approximately 45 and 48 kDa), suggesting that these two forms of PAC1R represent
core proteins. Flow cytometric analysis indicated that the agonist promoted a disappearance of cell surface receptor. In
accordance with this observation, preexposure of cells to PACAP38 induced a desensitization of PAC1R to the agonist
response, although it did not cause a reduction in PAC1R mRNA or protein level and even slightly elevated them. These
results suggest that agonist-induced desensitization of PAC1R involves the receptor sequestration. ß 2000 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Pituitary adenylate cyclase-activating polypeptide
(PACAP) has an amino acid sequence identity of
68% with vasoactive intestinal polypeptide (VIP), in-
dicating that it is a member of the VIP/secretin/glu-
cagon/growth hormone-releasing hormone family.
PACAP exists in two amidated forms, PACAP38
and PACAP27, sharing the same N-terminal 27 ami-
no acids [1,2]. PACAP regulates a wide range of
physiological functions in the central and peripheral
nervous systems as a hypophysiotropic hormone,
neurotransmitter, neuromodulator, and vasoregula-
tor [1^3]. Molecular cloning studies have shown
that these actions of PACAP are mediated by recep-
tors encoded by at least three di¡erent genes. VIP1
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(VPAC1) and VIP2 (VPAC2) receptors binds VIP
and PACAP with similar a⁄nities, whereas PACAP
(PAC1) receptor speci¢cally binds PACAP [4^6].
Previously, we cloned cDNA for PAC1 receptor
(PAC1R) [5,7], isolated genes for PAC1R, VPAC1
receptor and the PACAP ligand and determined their
structural organization [8^10]. In order to under-
stand the functional meanings of PAC1R, we have
initially revealed its localization in the rat brain,
adrenal gland and superior cervical ganglion by in
situ hybridization histochemistry [11^13], and more
recently, we have generated PAC1R exon 2-de¢cient
mice (submitted elsewhere).
Aimura and coworkers generated a polyclonal rab-
bit antibody directed against a 25-residue polypep-
tide corresponding to the C-terminal intracellular do-
main of the rat PAC1R, which have proven
invaluable in the detection and localization of the
receptor protein [14]. At present, however, the suc-
cessful production of antibody to the ectodomain of
PAC1R, which can detect the receptor protein on the
intact cells, has not yet been reported. Previously, we
tried to make antibodies in rabbits by immunizing
with a fusion protein consisting of glutathione-S-
transferase and the N-terminal extracellular domain
of the rat PAC1R which was produced in Escherichia
coli. The resultant sera, however, contained very low-
titer antibodies which reacted only poorly with
PAC1R expressed in mammalian cells, probably be-
cause of a high degree of glycosylation of the recep-
tor protein (unpublished observation).
In the present study, we have generated hemagglu-
tinin (HA) epitope-tagged PAC1R (HA-PAC1R), in
which the epitope tag was placed in the N-terminal
extracellular domain, to facilitate immunological de-
tection of PAC1R both in intact and permeabilized
cells, and £ow cytometric analysis, and studied sub-
cellular localization, posttranslational processing (es-
pecially glycosylation), and desensitization of
PAC1R.
2. Materials and methods
2.1. Construction of the hemagglutinin (HA)
epitope-tagged PAC1R (HA-PAC1R)
The HA-PAC1R was created by converting the se-
quence WMTETIGDS (residues 70^78) within the
N-terminal extracellular domain of the mouse
PAC1R to the 9-amino-acid HA epitope (sequence
YPYDVPDYA) recognized by the monoclonal anti-
body 12CA5 [15]. The HA sequence was introduced
into the mouse PAC1R cDNA clone pCAPM17 [7]
by oligonucleotide-directed mutagenesis using TAA
GAC CAA GTC TAC CCC TAC GAT GTC
CCC GAC TAC GCT GGC TTT GCT GAT
AGT AAT TCC oligonucleotide. The mutated and
adjacent regions were con¢rmed by restriction en-
zyme mapping and DNA sequencing analyses. The
resultant plasmid, designated pHA-CAPM17, as well
as pCAPM17 were transiently or stably expressed in
COS-7 and Chinese hamster ovary (CHO-K1) cells,
respectively.
2.2. Cells and transfection
COS-7 cells were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) containing
10% fetal calf serum, and were transiently transfected
with plasmids expressing pHA-CAPM17 or
pCAPM17 by the DEAE^dextran method as de-
scribed previously [5]. CHO-K1 cells were main-
tained in Ham’s F12 medium containing 10% fetal
calf serum. Stably transfected cells were established
by cotransfection of plasmids expressing pHA-
CAPM17 or pCAPM17 together with pSTneoB [16]
by electroporation and selecting with 0.6 mg/ml
G418. Clones were screened for expression of
the recombinant receptors by PACAP38-stimulated
cAMP production (both pHA-CAPM17 and
pCAPM17) and immuno£uorescent staining (pHA-
CAPM17).
2.3. Radioligand binding and cAMP assays
Crude membrane fractions were prepared from the
transiently transfected COS-7 cells 48 h after trans-
fection essentially as described previously [5]. Bind-
ing of [125I]PACAP27 to the membranes was assayed
as described [5]. To determine the nonspeci¢c bind-
ing, a large excess (1 WM) of unlabeled peptide was
included in the assay mixture. The membranes from
COS-7 cells transfected with the vector alone did not
show any signi¢cant binding of [125I]PACAP27.
cAMP production in transfected COS-7 cells was
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quanti¢ed with a [125I]cAMP assay kit as described
[17].
2.4. Immunoblot analysis of membrane fractions
Immunoblot analysis was performed as described
[18] with several modi¢cations. Brie£y, crude mem-
branes or cellular lysates prepared from the trans-
fected cells were reduced with dithiothreitol, resolved
by electrophoresis through sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE),
and transferred to Immobilon-P ¢lters (Millipore);
the ¢lters were blocked with 5% nonfat dry milk in
TBS-T and incubated with the ¢rst monoclonal anti-
body, 12CA5 [15], at a 1:1000 dilution followed by a
peroxidase-labeled antimouse second antibody.
Chemiluminescence was used for detection. Endogly-
cosidase F digestion of the membranes was per-
formed according to the manufacturer’s instruction
(New England Biolabs), except that the reaction was
performed at room temperature. Immuno£uores-
cence study was performed using £uorescein
(FITC)-labeled second antibody. Intact and NP40-
permeabilized (0.2% NP40, 30 min at 37‡C) cells
were blocked with DMEM containing 10% FCS
and 1% BSA, incubated with the ¢rst antibody at a
1:750 dilution followed by a FITC-labeled antimouse
second antibody, and examined using confocal mi-
croscopy. Flow cytometric analysis was performed
by FACS Calibrator (Molecular Dynamics) as de-
scribed [19].
2.5. Northern blot analysis and reverse
transcription^polymerase chain reaction
(RT^PCR)
After exposure to agonist, total cellular RNAs
were extracted from the transfected cells. As probes,
a 990 bp PstI DNA fragment of pCAPM17 [7] was
used. Northern hybridization was carried out under
high stringency essentially as described [5]. RT^PCR
was performed as described [20]. For PCR of mouse
PAC1R mRNA, the following oligonucleotides were
designed as primers: F10, 5P-AGC TGC ACT GTA
CCC GTA AC-3P (sense, corresponding to bases
692^711 [7]); R33, 5P-GCT GTG CTG TCA TTC
ATA TCC-3P (antisense, corresponding to bases
1044^1064 [7]). The PCR products were separated
by 1.5% agarose gel electrophoresis and stained
with £uorescent DNA binding dye, Vistra Green
(Amersham Pharmacia Biotech), then their £uores-
cence was measured with £uorescent image analyser,
FluorImager595 (Molecular Dynamics, Tokyo, Ja-
pan). The numbers of ampli¢cation and the amounts
of cDNAs used for the reaction were optimized for
quantitation of RNAs. The L-actin housekeeping
Fig. 1. Construction of hemagglutinin (HA) epitope-tagged PAC1R (HA-PAC1R). The nucleotide sequence and amino acid sequence
of the mouse PAC1R around exons 5 and 6 of the PAC1R gene, and the PCR primer used for oligonucleotide-directed mutagenesis
(italic letters) are shown. The HA-PAC1R was created by converting the sequence WMTETIGDS (residues 70^78) within the N-termi-
nal extracellular domain of the mouse PAC1R to the 9-amino-acid HA epitope (sequence YPYDVPDYA) recognized by the monoclo-
nal antibody 12CA5.
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gene was simultaneously reverse transcribed and am-
pli¢ed as the internal reference standard.
3. Results
3.1. Functional properties of HA-PAC1R
The mouse PAC1R [7] was tagged with the HA
antigen epitope at amino acids 70^78, a part of the
21-amino-acid sequence (amino acids 69^89) in the
N-terminal extracellular domain, which has no ho-
mologous domain in any other member of the VIP/
secretin/glucagon receptor family [5,7] and was en-
coded by exons 5 and 6 of the mouse PAC1R gene
[8] (Fig. 1). To study the functional properties of
HA-PAC1R, HA-PAC1R cDNA (pHA-CAPM17)
as well as PAC1R cDNA (pCAPM17) was trans-
fected into COS-7 cells and tested for the ability to
bind PACAP and to activate cAMP production. As
shown in Fig. 2, introduction of the HA nonapeptide
sequence did not alter the binding property and the
receptor activity, as compared with the wild-type
mouse PAC1R: HA-PAC1R displayed similar high-
a⁄nity binding properties for PACAP38 (for HA-
PAC1R, Kd = 0.92 nM and for PAC1R, Kd = 0.60
nM) and responded well to PACAP with increases
in cAMP generation. As PAC1R is also coupled to
activation of phospholipase C, and then it increases
the intracellular calcium concentration ([Ca2]i) [1],
we next examined PACAP-induced changes of
[Ca2]i in CHO-K1 cells stably transfected with the
wild-type PAC1R or HA-PAC1R by using single-cell
calcium imaging [18]. PACAP38 evoked [Ca2]i rise
through both receptors with pEC50 (3log EC50) of
7.6 (wild-type PAC1R) and 7.8 (HA-PAC1R) for the
peak [Ca2]i response and with pEC50 of 7.6 (wild-
type PAC1R) and 7.7 (HA-PAC1R) for the number
of responsive cells. PACAP27 also evoked [Ca2]i
rise with pEC50 of 7.8 (wild-type PAC1R) and 7.0
(HA-PAC1R) for the peak [Ca2]i response, while
VIP had no e¡ect on the calcium response.
3.2. Immunolocalization of HA-PAC1R in transiently
transfected COS-7 cells
Next, we studied the subcellular localization of
HA-PAC1R by immuno£uorescence microscopy. As
shown in Fig. 3a, nonpermeabilized COS-7 cells
transfected with HA-PAC1R showed intense staining
Fig. 2. Pharmacological characteristics of HA-PAC1R. (a) Accumulation of intracellular cAMP in COS7 cells transfected with the
HA-PAC1R (¢lled symbols) or PAC1R (open symbols) expression plasmid. The cells were incubated with various concentrations of
PACAP38 (circles) and VIP (squares), and the cAMP accumulated in the cells was quanti¢ed. Values are expressed as mean þ stan-
dard error of triplicate experiments. The results shown are representative of three independent experiments. (b) [125I]PACAP27 binding
to membranes from COS-7 cells transfected with PAC1R and HA-PAC1R cDNAs. COS-7 cells were transfected with the HA-PAC1R
(closed circles) or PAC1R (open circles) expression plasmid, and the membranes from the transfected cells were incubated with various
concentrations of [125I]PACAP27. Inset: Scatchard plot analysis of [125I]PACAP27 binding. Values are expressed as mean of duplicate
experiments. The results shown are representative of three independent experiments.
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of the plasma membrane, which was frequently ob-
served to be both di¡use and clustered at the plasma
membrane. Studies with permeabilized HA-PAC1R-
expressing cells revealed additional staining of intra-
cellular membrane structures with strong staining of
the nuclear perimeter (most likely the endoplasmic
reticulum/Golgi complex) (Fig. 3b). This staining
pattern of PAC1R immuno£uorescence was the
same over a wide range of receptor expression in
transiently transfected COS-7 cells. A similar pattern
was also obtained in CHO-K1 cells stably transfected
with HA-PAC1R (data not shown).
3.3. Immunoblot analysis of HA-PAC1R glycosylation
To examine the contribution of carbohydrate moi-
eties to the apparent molecular mass of PAC1R, we
used an inhibitor of N-glycosylation, tunicamycin, as
well as an endoglycosidase, endoglycosidase F/pep-
tide-N-glycosidase F, and performed immunoblot
analysis of HA-PAC1R expressed in COS-7 cells.
As shown in Fig. 4, the immunoreactive bands with
relative molecular masses ranging from 45 to 70 kDa
were detected in the crude membrane fractions of
HA-PAC1R-expressing COS-7 cells. A similar result
was obtained in the plasma membrane fractions
(data not shown). Treatment of the membranes
with endoglycosidase F decreased the size of the re-
ceptor to major bands of smaller size (approximately
45 and 48 kDa) with a faint broad band of 50^55
kDa. Treatment of the cells with tunicamycin de-
creased the size of PAC1R to two compact bands
of 45 and 48 kDa, suggesting that these two forms
of PAC1R represent core proteins.
Fig. 4. Immunoblot analysis of HA-PAC1R expressed in COS-7
cells. The crude membrane fractions of COS-7 cells transfected
with the PAC1R (lane 1) or HA-PAC1R (lanes 2^4) expression
plasmid were subjected to immunoblot analysis: lane 1, nega-
tive control; lane 2, nontreatment; lane 3, membranes treated
with 0.5 units/Wl endoglycosidase F; lane 4, membranes from
the cells cultured in a medium containing 1 Wg/ml tunicamycin
for 40 h. The results shown are representative of three inde-
pendent experiments.
Fig. 3. Cell surface and perinuclear distribution of HA-PAC1R studied by confocal immuno£uorescence microscopy. COS-7 cells were
transfected with the HA-PAC1R expression plasmid. Immuno£uorescence experiments were carried out with nonpermeabilized (a) or
permeabilized (b) cells. Each panel is representative of six independent experiments. Bar = 25 Wm.
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3.4. Agonist-dependent desensitization and
internalization of PAC1R
It has been reported that prolonged incubation of
CATH.a cells with PACAP attenuates agonist-stimu-
lated cAMP accumulation [21]. To determine
whether CHO cells transfected with PAC1R desensi-
tize in response to PACAP, PAC1R-expressing
CHO-K1 cells were pre-exposed to 100 nM PA-
CAP38 and then subsequently challenged by the
same concentration of PACAP. As shown in Fig.
5a, the cAMP response to PACAP38 added in the
second incubation gradually declined and maximal
desensitization was observed at 8 h (to about 40%
of the initial response to PACAP38). A similar result
was obtained in the cells pre-exposed to PACAP38
as low as 1 nM, and also in CHO cells stably trans-
fected with HA-PAC1R (data not shown). In accor-
dance with this observation, £ow cytometric analysis
revealed that the agonist promoted a disappearance
of cell surface receptor (Fig. 5b). However, PA-
CAP38 exposure did not cause a reduction in
PAC1R mRNA or protein level and even slightly
elevated them at 2^4 h (Fig. 5c). The results suggest
that agonist-dependent desensitization of the cAMP
response occurred via sequestration of PAC1R away
Fig. 5. Agonist-induced desensitization and internalization of HA-PAC1R in stably transfected CHO-K1 cells. (a) CHO-K1 cells ex-
pressing PAC1R were incubated for indicated time periods with 100 nM PACAP38, washed, and then the ability of a second PA-
CAP38 (100 nM) exposure to increase intracellular cAMP levels (closed circles), and basal cAMP level (open circle) were assayed. (b)
CHO-K1 cells expressing HA-PAC1R were incubated for indicated time periods with 100 nM PACAP38, and the cell surface expres-
sion was assessed by average £uorescence intensity per £uorescence-positive and propidium iodide-negative cells, which was analyzed
by £ow cytometry. (c) HA-PAC1R mRNA and protein levels. CHO-K1 cells expressing HA-PAC1R were incubated for indicated time
periods with 100 nM PACAP38. The cellular lysates (30 Wg) were subjected to immunoblot analysis, and 10 Wg and 5 ng of the total
cellular RNA were subjected to Northern blot analysis and RT^PCR analysis, respectively, as described in Section 2.
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from the cell surface rather than downregulation of
the receptors.
4. Discussion
The HA-PAC1R was created by converting the se-
quence within the 21 amino acid sequence in the N-
terminal extracellular domain to HA epitope. Muta-
tion of this region was selected for the following
reasons: (1) a suitable antibody which can recognize
the extracellular domain present on the cell surface
was not available; (2) the 21-amino-acid sequence
has no homologous domain in any other member
of the VIP/secretin/glucagon receptor family, and is
encoded by two alternative exons 5 and 6 of the
mouse PAC1R gene, which can be spliced out; (3)
the naturally occurring splicing variant missing the
21 amino acids has almost normal receptor function
(even slightly higher a⁄nity for PACAP27 than the
wild-type receptor) [22], suggesting that there is no
amino acid residue essential for the receptor function
in the 21-amino-acid sequence; and (4) the hydro-
pathy pro¢le of PAC1R suggests that the 21-amino-
acid sequence is hydrophilic and is, therefore, likely
to be on the surface of the molecule. The rationale
for choosing the HA epitope was that the Chou^
Fasman [23] and Garnier^Robson [24] predictions
both demonstrated only a small change in the sec-
ondary structure of the receptor protein when tagged
with HA epitope. Fortunately, this approach was
successful: introduction of the HA nonapeptide se-
quence did not alter the binding property and the
receptor activity, as compared with the native
PAC1R.
In immunoblot studies, treatment with endoglyco-
sidase F or tunicamycin decreased the size of HA-
PAC1R to compact bands of 45 and 48 kDa, sug-
gesting that these two forms of HA-PAC1R represent
core proteins. These apparent molecular masses of 45
and 48 kDa are the same as or close to that reported
for the human PAC1R (48 kDa) puri¢ed from Sf9
insect cells, in which incomplete glycosylation seems
occur [25]. However, these molecular masses are
slightly lower than the expected mass (54.5 kDa)
calculated from the amino acid sequence [7], suggest-
ing that they may represent truncated receptor
forms, although another possibility for proteolytic
degradation of the receptor protein cannot be ex-
cluded.
Studies with permeabilized HA-PAC1R-expressing
cells revealed strong staining of the nuclear perime-
ter, most likely the endoplasmic reticulum/Golgi
complex. The ¢nding that this staining pattern was
the same over a wide range of receptor expression in
transiently transfected COS-7 cells, and in stably
transfected CHO-K1 cells suggests that intracellular
retention of PAC1R is not simply the result of over-
expression. In pheochromocytoma PC12 cells, which
endogenously express PAC1R [13], HA-PAC1R was
localized both in the plasma membrane and the cy-
toplasm (data not shown). Intracellular retention has
also been reported for other G protein-coupled re-
ceptors, including the calcitonin receptor [26], para-
thyroid hormone (PTH)/PTH-related peptide recep-
tor [27], and thyrotropin-releasing hormone receptor
[28], although cell type-speci¢c di¡erences in receptor
localization has been demonstrated in thyrotropin-
releasing hormone receptor [28].
In desensitization studies, pretreatment of CHO-
K1 cells expressing PAC1R with PACAP38 caused
a reduction of PACAP-stimulated cAMP accumula-
tion and a disappearance of cell surface receptor in a
parallel manner. These results showed for the ¢rst
time that agonist-induced PAC1R desensitization at
least partly involves mechanisms underlying the se-
questration of the receptors away from the cell sur-
face. Although the receptor sequestration may not
entirely explain the observed desensitization, down-
regulation of the receptor protein or mRNA levels is
unlikely to be involved. Possible mechanisms of
PAC1R sequestration include clathrin-mediated en-
docytosis and a caveolin-dependent mechanism [29].
To investigate the desensitization of PAC1R under
natural physiological conditions, PACAP-induced
desensitization of cAMP signaling was examined in
rat cultured astrocytes, which endogenously express a
relatively low level of PAC1R ([5] and our unpub-
lished observation). Pre-exposure of the cells to PA-
CAP38 reduced the cAMP response, similarly to
what was seen in CHO cells (data not shown),
although we could not examine the sequestration of
PAC1R. A future study is necessary to investigate the
sequestration of the native PAC1R into the intracel-
lular compartment by using an antibody recognizing
the native PAC1R.
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In summary, PAC1R was tagged with HA epitope
at the N-terminal extracellular domain without loss
of functions in ligand binding, cAMP production,
and [Ca2]i elevation. By using HA-PAC1R, we per-
formed immunocytochemical, immunoblot, and £ow
cytometric analyses to study subcellular localization,
posttranslational processing (especially glycosyla-
tion), and desensitization of PAC1R. HA-PAC1R
was expressed both in the plasma membrane and
the cytoplasm with relative molecular masses ranging
from 45 to 70 kDa and core proteins being 45 and 48
kDa. Agonist-induced desensitization of PAC1R-
mediated cAMP accumulation paralleled a disap-
pearance of cell surface receptor. This epitope-tagged
PAC1R will be valuable for further studies on the
posttranslational processing, especially glycosylation,
plasma membrane sorting, and sequestration/inter-
nalization of PAC1R.
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